日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial

伊布替尼联合利妥昔单抗对比免疫化疗治疗既往未接受治疗的套细胞淋巴瘤患者(ENRICH):一项随机、开放标签、2/3期优效性试验

Lewis, David J; Jerkeman, Mats; Sorrell, Lexy; Wright, David; Glimelius, Ingrid; Poulsen, Christian B; Pasanen, Annika; Rawstron, Andrew; Wader, Karin F; Morley, Nick; Burton, Catherine; Davies, Andrew J; Lagerlöf, Ingemar; Dalal, Surita; De Tute, Ruth; McNamara, Chris; Crosbie, Nicola; Toldbod, Helle Erbs; Sanders, Jeanette; Allgar, Victoria; Aroori, Sree; Warner, Mark; Scully, Claire; Wainman, Brian; Christensen, Jacob Haaber; Riise, Jon; Sonnevi, Kristina; Bishton, Mark J; Eyre, Toby A; Rule, Simon

Excised DNA circles from V(D)J recombination promote relapsed leukaemia

V(D)J重组产生的DNA环促进白血病复发。

Gao, Zeqian; Scott, James N F; Edwards, Matthew P; Casey, Dylan; Wang, Xiaoling; Gillen, Andrew D; Ryan, Sarra; Russell, Lisa J; Moorman, Anthony V; de Tute, Ruth; Cargo, Catherine; Ford, Anthony M; Westhead, David R; Boyes, Joan

Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling

通过转录组和基因谱分析挑战功能性高危骨髓瘤的概念

Beer, Sina A; Cairns, David A; Pawlyn, Charlotte; Holroyd, Amy; Ferris, Elsa; Cook, Gordon; Drayson, Mark; Boyd, Kevin; Proszek, Paula; Davies, Faith E; de Tute, Ruth; Jenner, Matthew; Morgan, Gareth J; Owen, Roger; Hubank, Michael; Houlston, Richard; Jackson, Graham; Kaiser, Martin F

Doubling in median survival in patients diagnosed with multiple myeloma 2005-2019; a real-world study from the UK's Haematological Malignancy Research Network

英国血液恶性肿瘤研究网络的一项真实世界研究表明,2005年至2019年间,多发性骨髓瘤患者的中位生存期翻了一番。

Smith, Alexandra; Bagguley, Timothy; Roman, Eve; Crouch, Simon; Patmore, Russell; De Tute, Ruth; Rawstron, Andy; Cook, Gordon; Seymour, Frances; Parrish, Christopher

Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrőm macroglobulinaemia

在R2W试验中,硼替佐米联合环磷酰胺和利妥昔单抗治疗华氏巨球蛋白血症,通过骨髓B细胞清除评估长期疗效

de Tute, Ruth; Counsell, Nicholas; Clifton-Hadley, Laura; D'Sa, Shirley; Pratt, Guy; Campbell, Gavin; Campbell, Lauren; Sadler, Ross; Townsend, William; Popova, Bilyana; Smith, Paul; Schofield, Oliver; Owen, Roger; Auer, Rebecca

Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry

多发性骨髓瘤患者免疫固定电泳(IFE)转阴后,其无进展生存期与质谱法检测到残留单克隆游离轻链(FLC)相关。

Giles, H V; Drayson, M T; Kishore, B; Pawlyn, C; Kaiser, M; Cook, G; de Tute, R; Owen, R G; Cairns, D; Menzies, T; Davies, F E; Morgan, G J; Pratt, G; Jackson, G H

PembroWM: A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia

PembroWM:一项 II 期临床试验,旨在研究利妥昔单抗和帕博利珠单抗治疗复发/难治性华氏巨球蛋白血症的安全性和有效性。

Kothari, Jaimal; Eyre, Toby; Rismani, Ali; Ediriwickrema, Kushani; Edwards, Darren; Galani, Sevasti; Wilson, William; Lawrie, Anthony; Clifton-Hadley, Laura; McCarthy, Helen; Collins, Angela; Lewis, David; Arulogan, Suzanne; Auer, Rebecca; Pratt, Guy; de Tute, Ruth; Owen, Roger; D'Sa, Shirley

Targeted Data Quality Analysis for a Clinical Decision Support System for SIRS Detection in Critically Ill Pediatric Patients

针对危重儿科患者全身炎症反应综合征(SIRS)检测的临床决策支持系统进行目标数据质量分析

Tute, Erik; Mast, Marcel; Wulff, Antje

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial

在初诊多发性骨髓瘤患者中,自体干细胞移植后风险和反应适应性治疗(RADAR(UK-MRA Myeloma XV 试验):一项 II/III 期随机对照试验的研究方案)

Royle, Kara-Louise; Coulson, Amy Beth; Ramasamy, Karthik; Cairns, David A; Hockaday, Anna; Quezada, Sergio; Drayson, Mark; Kaiser, Martin; Owen, Roger; Auner, Holger W; Cook, Gordon; Meads, David; Olivier, Catherine; Barnard, Lorna; Lambkin, Rhiannon; Paterson, Andrea; Dawkins, Bryony; Chapman, Mike; Pratt, Guy; Popat, Rakesh; Jackson, Graham; Bygrave, Ceri; Sive, Jonathan; de Tute, Ruth; Chantry, Andrew; Parrish, Christopher; Cook, Mark; Asher, Samir; Yong, Kwee

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial

卡非佐米、来那度胺、地塞米松和环磷酰胺(KRdc)作为适合移植的新诊断多发性骨髓瘤患者(骨髓瘤XI+)的诱导治疗:一项开放标签随机对照试验的中期分析

Jackson, Graham H; Pawlyn, Charlotte; Cairns, David A; de Tute, Ruth M; Hockaday, Anna; Collett, Corinne; Jones, John R; Kishore, Bhuvan; Garg, Mamta; Williams, Cathy D; Karunanithi, Kamaraj; Lindsay, Jindriska; Rocci, Alberto; Snowden, John A; Jenner, Matthew W; Cook, Gordon; Russell, Nigel H; Drayson, Mark T; Gregory, Walter M; Kaiser, Martin F; Owen, Roger G; Davies, Faith E; Morgan, Gareth J